about
Interplay between the levels of estrogen and estrogen receptor controls the level of the granzyme inhibitor, proteinase inhibitor 9 and susceptibility to immune surveillance by natural killer cellsNatural products as aromatase inhibitorsInteraction of TFAP2C with the estrogen receptor-alpha promoter is controlled by chromatin structureDeficits in plasma oestradiol measurement in studies and management of breast cancerOptimal management of hormone receptor positive metastatic breast cancer in 2016The Clinician's Toolbox: Assessing the Sexual Impacts of Cancer on Adolescents and Young Adults with Cancer (AYAC)Medical treatment of uterine leiomyomaDenosumab, a RANK ligand inhibitor, for the management of bone loss in cancer patientsDevelopment of new estrogen receptor-targeting therapeutic agents for tamoxifen-resistant breast cancerPharmGKB summary: very important pharmacogene information for cytochrome P-450, family 2, subfamily A, polypeptide 6Exemestane for breast cancer prevention: a critical shift?Adjuvant treatment for older women with invasive breast cancerReview of hormone-based treatments in postmenopausal patients with advanced breast cancer focusing on aromatase inhibitors and fulvestrantCardiac risk in the treatment of breast cancer: assessment and management.The Modern Landscape of Endocrine Therapy for Premenopausal Women with Breast CancerGenetic modifiers of menopausal hormone replacement therapy and breast cancer risk: a genome-wide interaction study.Everolimus in postmenopausal hormone-receptor-positive advanced breast cancerCancer drug related cardiotoxicity during breast cancer treatment.Impact of mutational profiles on response of primary oestrogen receptor-positive breast cancers to oestrogen deprivationHeel ultrasound can assess maintenance of bone mass in women with breast cancer.Uterine fibroids: current perspectivesNeoadjuvant letrozole in postmenopausal estrogen and/or progesterone receptor positive breast cancer: a phase IIb/III trial to investigate optimal duration of preoperative endocrine therapy.Coprescription of Chinese herbal medicine and Western medication among female patients with breast cancer in Taiwan: analysis of national insurance claimsPhospho-kinase profile of triple negative breast cancer and androgen receptor signaling.Ultra-low-dose estriol and Lactobacillus acidophilus vaginal tablets (Gynoflor(®)) for vaginal atrophy in postmenopausal breast cancer patients on aromatase inhibitors: pharmacokinetic, safety, and efficacy phase I clinical study.A polymorphism at the 3'-UTR region of the aromatase gene defines a subgroup of postmenopausal breast cancer patients with poor response to neoadjuvant letrozole.Letrozole induced hypercalcemia in a patient with breast cancer.Status of adjuvant endocrine therapy for breast cancer.Aromatase inhibitors-induced bone loss in early breast cancer.The Importance of Steroid Uptake and Intracrine Action in Endometrial and Ovarian Cancers.Managing aromatase inhibitors in breast cancer survivors: not just for oncologistsReversion of Hormone Treatment Resistance with the Addition of an mTOR Inhibitor in Endometrial Stromal Sarcoma.Design, conduct, and analyses of Breast International Group (BIG) 1-98: a randomized, double-blind, phase-III study comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive, early breast cancerAntibody responses to NY-ESO-1 in primary breast cancer identify a subtype target for immunotherapy.Detection of estrogen-independent growth-stimulating activity in breast cancer tissues: implication for tumor aggressivenessEffects of switching from anastrozole to letrozole, due to reimbursement policy, on the outcome of breast cancer therapyChanges in expression of oestrogen regulated and proliferation genes with neoadjuvant treatment highlight heterogeneity of clinical resistance to the aromatase inhibitor, letrozoleMedical treatment of early breast cancer. II: endocrine therapyCharacterization of estrogen-receptor-targeted contrast agents in solution, breast cancer cells, and tumors in vivo.In vitro and in vivo oxidative metabolism and glucuronidation of anastrozole.
P2860
Q24293644-C2BD7569-CCF3-4AAA-A5C5-833C3A900122Q24620153-55E16300-63A0-4B3F-B80B-C32E89FF5BC5Q24657263-F0DF3475-0FCD-4491-839F-5EC173DABCAEQ24796747-0F464803-FB1A-4F39-9249-0E1A713DDAF5Q26777683-017308E7-C59A-401C-868C-D82613DABBF7Q26782823-EB2FFCC0-4171-489F-A1B7-8BDEA058BAB2Q26824379-F01D4D7C-2A2E-468B-90AF-8C018891190EQ26824762-B98AE561-FD9B-4C50-AD58-79A6BFCC17EFQ26825584-B29E4B16-FACF-4A38-8BEF-A34B52B5687BQ27012807-7E0E169D-FCF4-4CE1-8B22-E88438FC1172Q27028211-EA210112-6B3C-45EA-92B7-9C05ECEB5404Q28066744-A3C60738-B222-480F-B8A1-AF117CBDD13CQ28076777-AD86D52A-7895-4BA4-897E-4B83D11293D3Q28081385-910B7542-71C7-4A83-A9FB-D0445067A5F8Q28085160-B0C15B09-A75D-47B9-B643-EF1A1BA89588Q29417068-B927003C-30EE-406E-ADF6-CFCB0DA0FAFCQ29620676-945654B8-9B9D-446B-BC8E-043B506528BAQ30251498-BA489668-9A6B-4E78-B0E3-CE71D52284D6Q30369607-EBA38284-43F1-473A-9818-B9DAB5D30064Q30383587-71A4599A-57C4-45C0-A47B-7D5C1A2B3D7CQ30443242-9F853728-93D4-41E0-9072-FEA69A52CEF5Q33321322-00ED5352-B72F-4955-A217-9D547C7DC194Q33604877-C73D7AE5-B886-4692-93B2-9072A2776DFDQ33612132-36360E0A-3190-47CD-AE9C-FCC3AF81DEDAQ33628455-CE1B2A85-82CC-4CF5-8ABC-73F367F19728Q33694817-70F7D486-5B78-4B50-BE80-E69EAFD1FADBQ33737423-001E7C63-9B4E-4643-95BA-128ED93EA9FEQ33739138-9E292DA2-1911-4D7B-A633-A762DC3E95D2Q33752867-856A1A25-E7C1-466D-8FB4-6252144426FCQ33809605-244C8AE0-63EE-4C59-9E76-37C470C5CD4CQ33884184-4604D967-A982-4482-B7AA-4B7E4C6461ECQ33943265-19287970-9B7E-489D-8BC7-358E9D9C1663Q33944557-5F5DB20E-58DF-42C3-83A0-23B1A26607ABQ33957896-7B892117-18BB-4D47-A81E-E9ACBD3DEA14Q34115972-2E1EE791-4AB9-4456-A2D9-BBC2E10CE9EEQ34134780-8AC175F4-DF90-4E05-8747-86A8D93E86D9Q34173468-321B73EF-E30E-4FFA-86A0-4ACEFEF5DB0DQ34251085-4B440122-DAF3-4CF5-83FC-55EB69EEE711Q34377637-084927A7-1A6F-49E5-99D9-47ABB83EB1A0Q34457429-CD096FE5-30CF-46DA-A8C7-9B68CB7C2129
P2860
description
2003 nî lūn-bûn
@nan
2003 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Aromatase inhibitors in breast cancer.
@ast
Aromatase inhibitors in breast cancer.
@en
type
label
Aromatase inhibitors in breast cancer.
@ast
Aromatase inhibitors in breast cancer.
@en
prefLabel
Aromatase inhibitors in breast cancer.
@ast
Aromatase inhibitors in breast cancer.
@en
P356
P1476
Aromatase inhibitors in breast cancer.
@en
P2093
Ian E Smith
P304
P356
10.1056/NEJMRA023246
P407
P577
2003-06-01T00:00:00Z